Latest & greatest articles for pneumonia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pneumonia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pneumonia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pneumonia

121. Antibiotics for pediatric inpatients with community-acquired pneumonia

Antibiotics for pediatric inpatients with community-acquired pneumonia

2017 DynaMed Plus

122. Antibiotics for adult outpatients with community-acquired pneumonia

Antibiotics for adult outpatients with community-acquired pneumonia

2017 DynaMed Plus

131. Cohort study: Oral antibiotics are as effective as intravenous antibiotics for postdischarge treatment of complicated pneumonia in children

Cohort study: Oral antibiotics are as effective as intravenous antibiotics for postdischarge treatment of complicated pneumonia in children Oral antibiotics are as effective as intravenous antibiotics for postdischarge treatment of complicated pneumonia in children | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oral antibiotics are as effective as intravenous antibiotics for postdischarge treatment of complicated pneumonia

2017 Evidence-Based Medicine

132. Cohort study: General practices that reduce antibiotic prescribing for self-limiting respiratory tract infections by 10% can expect to see one extra patient with pneumonia each year and one peritonsillar abscess each decade

Cohort study: General practices that reduce antibiotic prescribing for self-limiting respiratory tract infections by 10% can expect to see one extra patient with pneumonia each year and one peritonsillar abscess each decade General practices that reduce antibiotic prescribing for self-limiting respiratory tract infections by 10% can expect to see one extra patient with pneumonia each year and one peritonsillar abscess each decade | BMJ Evidence-Based Medicine We use cookies to improve our (...) * Password * your user name or password? You are here General practices that reduce antibiotic prescribing for self-limiting respiratory tract infections by 10% can expect to see one extra patient with pneumonia each year and one peritonsillar abscess each decade Article Text Therapeutics/Prevention Cohort study General practices that reduce antibiotic prescribing for self-limiting respiratory tract infections by 10% can expect to see one extra patient with pneumonia each year and one peritonsillar

2017 Evidence-Based Medicine

134. A cleaner burning biomass-fuelled cookstove intervention to prevent pneumonia in children under 5 years old in rural Malawi (the Cooking and Pneumonia Study): a cluster randomised controlled trial. Full Text available with Trip Pro

A cleaner burning biomass-fuelled cookstove intervention to prevent pneumonia in children under 5 years old in rural Malawi (the Cooking and Pneumonia Study): a cluster randomised controlled trial. WHO estimates exposure to air pollution from cooking with solid fuels is associated with over 4 million premature deaths worldwide every year including half a million children under the age of 5 years from pneumonia. We hypothesised that replacing open fires with cleaner burning biomass-fuelled (...) cookstoves would reduce pneumonia incidence in young children.We did a community-level open cluster randomised controlled trial to compare the effects of a cleaner burning biomass-fuelled cookstove intervention to continuation of open fire cooking on pneumonia in children living in two rural districts, Chikhwawa and Karonga, of Malawi. Clusters were randomly allocated to intervention and control groups using a computer-generated randomisation schedule with stratification by site, distance from health

2016 Lancet Controlled trial quality: predicted high

135. Multidrug-resistant bacteria among patients with ventilator-associated pneumonia in an emergency intensive care unit, Egypt

Multidrug-resistant bacteria among patients with ventilator-associated pneumonia in an emergency intensive care unit, Egypt Multidrug-resistant bacteria among patients with ventilator-associated pneumonia in an emergency intensive care unit, Egypt JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links Multidrug-resistant bacteria among patients with ventilator-associated pneumonia (...) in an emergency intensive care unit, Egypt View/ Open View Statistics Altmetrics Share Abstract Ventilator-associated pneumonia [‎VAP]‎ is the most common hospital-acquired infection among mechanically ventilated patients. Our objectives were to determine the incidence of VAP, isolate multidrug-resistant bacteria, identify the most prevalent resistant strains and identify their antibiotic susceptibility pattern. The VAP rate was calculated. The isolated microbes were identified and tested for antibiotic

2016 WHO

136. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. Full Text available with Trip Pro

Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. Objective To examine the risk of community acquired pneumonia before and after prescription of proton pump inhibitor (PPI) and assess whether unmeasured confounding explains this association.Design Cohort study and self controlled case series.Setting Clinical Practice Research Datalink (1990 to 2013) in UK.Participants Adult patients with a new prescription for a PPI individually (...) matched with controls.Main outcome measures Association of community acquired pneumonia with PPI prescription estimated by three methods: a multivariable Cox model comparing risk in PPI exposed patients with controls, corrected for potential confounders; a self controlled case series; and a prior event rate ratio (PERR) analysis over the 12 month periods before and after the first PPI prescription.Results 160 000 new PPI users were examined. The adjusted Cox regression showed a risk of community

2016 BMJ

137. Antibiotics for treating community-acquired pneumonia in people with sickle cell disease. Full Text available with Trip Pro

Antibiotics for treating community-acquired pneumonia in people with sickle cell disease. As a consequence of their condition, people with sickle cell disease are at high risk of developing an acute infection of the pulmonary parenchyma called community-acquired pneumonia. Many different bacteria can cause this infection and antibiotic treatment is generally needed to resolve it. There is no standardized approach to antibiotic therapy and treatment is likely to vary from country to country (...) . Thus, there is a need to identify the efficacy and safety of different antibiotic treatment approaches for people with sickle cell disease suffering from community-acquired pneumonia. This is an update of a previously published Cochrane Review.To determine the efficacy and safety of the antibiotic treatment approaches (monotherapy or combined) for people with sickle cell disease suffering from community-acquired pneumonia.We searched The Group's Haemoglobinopathies Trials Register (01 September

2016 Cochrane

138. A semi-synthetic oligosaccharide conjugate vaccine candidate confers protection against Streptococcus pneumoniae serotype 3 infection Full Text available with Trip Pro

A semi-synthetic oligosaccharide conjugate vaccine candidate confers protection against Streptococcus pneumoniae serotype 3 infection The identification of immunogenic glycotopes that render glycoconjugate vaccines protective is key to improving vaccine efficacy. Synthetic oligosaccharides are an attractive alternative to the heterogeneous preparations of purified polysaccharides that most marketed glycoconjugate vaccines are based on. To investigate the potency of semi-synthetic (...) glycoconjugates, we chose the least-efficient serotype in the current pneumococcal conjugate vaccine Prevnar 13, Streptococcus pneumoniae serotype 3 (ST3). Glycan arrays containing synthetic ST3 repeating unit oligosaccharides were used to screen a human reference serum for antibodies and to define the recognition site of two ST3-specific protective monoclonal antibodies. The glycan array screens identified a tetrasaccharide that was selected for in-depth immunological evaluation. The tetrasaccharide-CRM197

2016 Cell chemical biology

139. Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia Full Text available with Trip Pro

Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia In a double-blind, randomised, placebo-controlled trial of hospitalised patients with community-acquired pneumonia (CAP), we demonstrated shorter time to clinical stability (TTCS) with adjunct corticosteroid therapy compared with placebo.We did a pre-planned, exploratory analysis of any association between microbiological diagnosis, antibiotic treatment and procalcitonin level and effect of prednisone (...) subgroups. We found evidence for a different prednisone response in patients with pneumococcal pneumonia in whom intravenous antibiotic duration was not shorter (interaction p=0.01) with prednisone, as was observed in the remaining study population. In patients without macrolide treatment, rehospitalisations were not lower with prednisone (interaction p=0.04). After adjustment for multiple testing, these subgroup effects were no longer significant.Prednisone was associated with shorter TTCS independent

2016 EvidenceUpdates

140. Ventilator associated events should trump ventilator associated pneumonia Full Text available with Trip Pro

Ventilator associated events should trump ventilator associated pneumonia 28979524 2019 01 16 1751-1437 17 4 2016 Nov Journal of the Intensive Care Society J Intensive Care Soc Ventilator associated events should trump ventilator associated pneumonia. 358 10.1177/1751143716651290 Thomas Matt M Intensive Care Medicine, North Bristol NHS Trust, Bristol, UK. eng Journal Article 2016 10 25 England J Intensive Care Soc 101538668 1751-1437 2017 10 6 6 0 2017 10 6 6 0 2017 10 6 6 1 ppublish 28979524

2016 Journal of the Intensive Care Society